|
|
Profile
|
Delegates :
Masaaki Fujiwara |

|
Incorporated :
March 30 , 2026 |
Paid in Capital :
10 Million yen |
Employees :
6 人 |
Address :
2F Success Ginza East Building, 1-13-10 Tsukiji, Chuo-ku TOKYO
〒104-0045
|
TEL/FAX :
/ |
URL:
https://castbio.co.jp/ |
Attachment :
|
Mission/Background :
Founded in 2026, CAST Bio develops antibody-drug conjugates (ADCs) targeting tumor stroma. Its lead candidate, CB-IF-01, uses insoluble fibrin (IF) deposited in tumor stroma as an anchor for drug delivery and is designed to release its payload locally through a proprietary VLK linker cleaved by constantly activate plasmin. By avoiding the need for binding to and internalization by tumor-cell surface antigens, this approach aims to address difficult-to-treat solid tumors with heterogeneous antigen expression. Starting with glioblastoma (GBM) and pancreatic ductal adenocarcinoma (PDAC), CAST Bio envisions biomarker-guided expansion into additional tumor types. Led by a team with R&D and clinical development experience at major pharmaceutical companies, CAST Bio is building partnerships with global pharma.
Keywords ADC, Antibody-Drug Conjugate, Cancer Stromal Targeting, CAST, VLK Linker, Oncology, Tumor Stroma, Glioblastoma, Pancreatic Cancer, Drug Discovery, Biotechnology |
|
Technology & Business
|
CB-IF-01, CAST Bio's lead program, is a tumor stroma-targeted ADC comprising an anti-insoluble fibrin (IF) antibody, a plasmin-cleavable VLK linker, and MMAE. By combining localization to tumor stroma with local fibrinolytic activity, it is designed to release MMAE extracellularly in the tumor microenvironment without relying on tumor-cell surface antigen expression. In preclinical studies, CB-IF-01 showed extension of survival time in an orthotopic GBM model (in brain) and in a KPC pancreatic cancer model. Preliminary safety findings have been encouraging. High-quality non-GMP material has been manufactured, and preparations for GMP manufacturing are in place. IF deposition has been confirmed in multiple human solid tumor types, with biomarker research underway to guide indication expansion. Pharmacology, safety, PK, CMC, and biomarker development are progressing toward a planned first-in-human trial in Japan in 2028.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
CB-IF-01 (IF-targeted ADC)
|
Preclinical
|
An ADC that binds insoluble fibrin and locally releases MMAE via a plasmin-cleavable linker.
|
Advance nonclinical safety, CMC and biomarker development toward a planned first-in-human trial in 2028.
|
VLK Linker Technology
|
Discovery
|
Proprietary plasmin-cleavable ADC linker which releases the payload both in the tumor stroma and within cancer cells.
|
Multiple ADC constructs with other antibody-payload combinations manufactured; preclinical studies underway.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highlights
|
Since its founding in March 2026, CAST Bio has secured pre-seed financing and built a leadership and development team with experience in pharmaceutical research, clinical development, and business development. It is strengthening its operating foundation through collaborations with CDMOs and CROs in Japan and overseas. CAST Bio also maintains dialogue with over a dozen major pharmaceutical companies to refine its development strategy and explore opportunities for global alliances and future M&A.
|
|
Alliance strategy
|
CAST Bio's long-term goal is an acquisition by a global pharmaceutical company. It welcomes early scientific and business dialogue with pharma partners on the R&D, clinical development and global expansion of its lead asset, CB-IF-01, and on broader applications of enabling technologies such as the VLK linker. It is open to flexible collaborations, including joint research, co-development, technology evaluation and licensing, tailored to each program's stage and mutual interests.
|
|
|